Lixivaptan
Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.
Product Specifications
CAS Number
[168079-32-1]
Product Name Alternative
VPA-985; WAY-VPA 985
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Vasopressin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Lixivaptan.html
Purity
99.67
Solubility
DMSO : ≥ 150 mg/mL
Smiles
O=C(C1=C(Cl)C=C(NC(C2=CC(F)=CC=C2C)=O)C=C1)N(C3)C4=CC=CC=C4CN5C3=CC=C5
Molecular Formula
C27H21ClFN3O2
Molecular Weight
473.93
Precautions
H302, H315, H319, H335
References & Citations
[1]Albright JD, et al. 5-Fluoro-2-methyl-N-[4- (5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10 (11H) -ylcarbonyl) -3-chlorophenyl]benzamide (VPA-985) : an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem. 1998 Jul 2;41 (14) :2442-4.|[2]Ghali JK, et al. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs. 2010 Nov;13 (11) :782-92.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
V2 Receptor
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PMIRH412PA-1 Bacterial Streak
Human pre-microRNA Expression Construct Lenti-miR-412+369+409 MI0000777, MI0001735,
Ask
View Details 
137979-PE 100 µL
FKTN (Fukutin, Fukuyama-type Congenital Muscular Dystrophy Protein, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4, MGC126857, MGC134944, MGC134945, MGC138243) (PE)
Ask
View Details